0      0

eSymposia | Advances in Cancer Immunotherapy


Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells


Aug 17, 2020 12:00am ‐ Aug 17, 2020 12:00am

Description

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells
Background: Dendritic cells (DC) are crucial for the efficacy of cancer vaccines, but current vaccines do not harness the key cDC1 subtype required for effective CD8+ T cell mediated tumor immune responses. Vaccine immunogenicity could be enhanced by specific delivery of immunogenic tumor antigens to CD141+ DC, the human cDC1 equivalent. CD141+ DC exclusively express the C-type-lectin-like receptor CLEC9A, which is important for the regulation of CD8+ T cell responses. This study developed a new vaccine that harnesses a human anti-CLEC9A antibody to specifically deliver the immunogenic tumor antigen, NY-ESO-1 to human CD141+ DC. The ability of the CLEC9A-NY-ESO-1 antibody to activate NY-ESO-1 specific naïve and memory CD8+ T cells was examined and compared to a vaccine comprised of a human DEC-205-NY-ESO-1 antibody that targets all human DC.
Methods: Human
anti-CLEC9A, anti-DEC-205 and isotype control IgG4 antibodies were genetically
fused to NY-ESO-1 polypeptide. Cross-presentation to NY-ESO-1- epitope specific
CD8+ T cells and reactivity of T cell responses in melanoma patients was
assessed by IFNγ production following incubation of CD141+ DC and patient
peripheral blood mononuclear cells with targeting antibodies. Humanized mice
containing human DC subsets and a repertoire of naïve NY-ESO-1-specific CD8+ T
cells were used to investigate naïve T cell priming. T cell effector function
was measured by expression of IFNγ, MIP-1β, TNF and CD107a and by lysis of
target tumor cells.
Results: CLEC9A-NY-ESO-1
Ab were effective at mediating delivery and cross-presentation of multiple
NY-ESO-1 epitopes by CD141+ DC for activation of NY-ESO-1-specific CD8+ T
cells. When benchmarked to NY-ESO-1 conjugated to an untargeted control
antibody or to anti-human DEC-205, CLEC9A-NY-ESO-1 was superior at ex vivo reactivation of NY-ESO-1-specific T
cell responses in melanoma patients. Moreover, CLEC9A-NY-ESO-1 induced priming
of naïve NY-ESO-1-specific CD8+ T cells with polyclonal effector function and
potent tumor killing capacity in vitro.
Conclusions: These data advocate human CLEC9A-NY-ESO-1
antibody as an attractive strategy for specific targeting of CD141+ DC to
enhance tumour immunogenicity in NY-ESO-1-expressing malignancies.

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content